1. Home
  2. ALLT vs CCCC Comparison

ALLT vs CCCC Comparison

Compare ALLT & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allot Ltd.

ALLT

Allot Ltd.

HOLD

Current Price

$9.83

Market Cap

429.1M

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$2.50

Market Cap

240.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALLT
CCCC
Founded
1996
2015
Country
Israel
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
429.1M
240.3M
IPO Year
2006
2020

Fundamental Metrics

Financial Performance
Metric
ALLT
CCCC
Price
$9.83
$2.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$12.75
$8.50
AVG Volume (30 Days)
445.1K
1.4M
Earning Date
11-20-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$98,512,000.00
$30,108,000.00
Revenue This Year
$12.44
N/A
Revenue Next Year
$12.98
N/A
P/E Ratio
$460.39
N/A
Revenue Growth
7.51
N/A
52 Week Low
$4.37
$1.09
52 Week High
$11.42
$4.70

Technical Indicators

Market Signals
Indicator
ALLT
CCCC
Relative Strength Index (RSI) 55.96 49.03
Support Level $9.68 $2.50
Resistance Level $10.35 $2.69
Average True Range (ATR) 0.39 0.18
MACD 0.10 -0.01
Stochastic Oscillator 62.50 23.86

Price Performance

Historical Comparison
ALLT
CCCC

About ALLT Allot Ltd.

Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Share on Social Networks: